358 related articles for article (PubMed ID: 36177913)
1. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA
Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913
[TBL] [Abstract][Full Text] [Related]
2. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
[TBL] [Abstract][Full Text] [Related]
4. Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer.
Kishi N; Matsuo Y; Shintani T; Ogura M; Mitsuyoshi T; Araki N; Fujii K; Okumura S; Nakamatsu K; Kishi T; Atsuta T; Sakamoto T; Ohtsu S; Katagiri T; Narabayashi M; Fujishiro S; Iizuka Y; Ozasa H; Hirai T; Mizowaki T;
J Radiat Res; 2023 Jan; 64(1):142-153. PubMed ID: 36149029
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results.
Verschueren MV; Dijs T; Gulikers JL; Veelen AV; Croes S; Hendriks LE; Smit AA; Bloem LT; Egberts AC; van de Garde EM; Peters BJ
Immunotherapy; 2023 Aug; 15(11):839-851. PubMed ID: 37291888
[TBL] [Abstract][Full Text] [Related]
6. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
Naidoo J; Antonia S; Wu YL; Cho BC; Thiyagarajah P; Mann H; Newton M; Faivre-Finn C
J Thorac Oncol; 2023 May; 18(5):657-663. PubMed ID: 36841540
[TBL] [Abstract][Full Text] [Related]
7. Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study.
Sugimoto T; Fujimoto D; Sato Y; Tamiya M; Yokoi T; Tamiya A; Iwasawa S; Hata A; Uchida J; Fukuda Y; Hara S; Kanazu M; Hirano K; Kokubo M; Yamamoto N
Invest New Drugs; 2021 Jun; 39(3):853-859. PubMed ID: 33405089
[TBL] [Abstract][Full Text] [Related]
8. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.
Chu CH; Chiu TH; Wang CC; Chang WC; Huang AC; Liu CY; Wang CL; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
Thorac Cancer; 2020 Jun; 11(6):1541-1549. PubMed ID: 32281272
[TBL] [Abstract][Full Text] [Related]
9. Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.
Kim DW; Chul Cho B; Pachipala K; Kim SW; Wang CL; Chang GC; Ahn MJ; Alvarez R; Chiu CH; Trigo J; Estival A; Karam SD; O'Brien C; Gowda H; Jiang H; Bauman JE
Lung Cancer; 2024 Apr; 190():107530. PubMed ID: 38471416
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations.
Cortiula F; De Ruysscher D; Steens M; Wijsman R; van der Wekken A; Alberti M; Hendriks LEL
Eur J Cancer; 2023 May; 184():172-178. PubMed ID: 36931075
[TBL] [Abstract][Full Text] [Related]
11. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.
Jung HA; Noh JM; Sun JM; Lee SH; Ahn JS; Ahn MJ; Pyo H; Ahn YC; Park K
Lung Cancer; 2020 Aug; 146():23-29. PubMed ID: 32505077
[TBL] [Abstract][Full Text] [Related]
12. Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer.
Mooradian MJ; Cai L; Wang A; Qiao Y; Chander P; Whitaker RM
JAMA Netw Open; 2024 Apr; 7(4):e247542. PubMed ID: 38648057
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Efficacy and Toxicity of Concurrent Chemoradiotherapy and Durvalumab and Concurrent Chemoradiotherapy Alone for Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Metastasis.
Abe T; Iino M; Saito S; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki YU; Miura YU; Kaira K; Kagamu H; Noda SE; Kato S
Anticancer Res; 2023 Feb; 43(2):675-682. PubMed ID: 36697072
[TBL] [Abstract][Full Text] [Related]
14. Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone.
Abe T; Saito S; Iino M; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S
Thorac Cancer; 2021 Jan; 12(2):245-250. PubMed ID: 33289347
[TBL] [Abstract][Full Text] [Related]
15. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study.
Takeda Y; Kusaba Y; Tsukita Y; Uemura Y; Miyauchi E; Yamamoto T; Mayahara H; Hata A; Nakayama H; Tanaka S; Uchida J; Usui K; Toyoda T; Tamiya M; Morimoto M; Oya Y; Kodaira T; Jingu K; Sugiura H
Clin Transl Radiat Oncol; 2022 Nov; 37():57-63. PubMed ID: 36065360
[TBL] [Abstract][Full Text] [Related]
16. Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).
Nakamichi S; Kubota K; Misumi T; Kondo T; Murakami S; Shiraishi Y; Imai H; Harada D; Isobe K; Itani H; Takata S; Wakui H; Misumi Y; Ikeda S; Asao T; Furuya N; Hosokawa S; Kobayashi Y; Takiguchi Y; Okamoto H
Clin Cancer Res; 2024 Mar; 30(6):1104-1110. PubMed ID: 38165684
[TBL] [Abstract][Full Text] [Related]
17. Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System.
Yegya-Raman N; Friedes C; Sun L; Iocolano M; Kim KN; Doucette A; Cohen RB; Robinson KW; Levin WP; Cengel KA; Lally B; Agarwal M; D'Avella CA; Marmarelis ME; Kosteva JA; Singh AP; Ciunci CA; Aggarwal C; Berman AT; Langer CJ; Feigenberg SJ
Clin Lung Cancer; 2023 Jul; 24(5):474-482. PubMed ID: 37076396
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy.
Araki T; Tateishi K; Komatsu M; Sonehara K; Wasamoto S; Koyama S; Yoshiike F; Hama M; Nishie K; Kondo D; Agatsuma T; Kato A; Takata M; Kanda S; Hanaoka M; Koizumi T
Thorac Cancer; 2022 Jul; 13(14):2031-2040. PubMed ID: 35616056
[TBL] [Abstract][Full Text] [Related]
19. Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
Socinski MA; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Gray JE; Park K; Vincent M; Mann H; Newton M; Dennis PA; Antonia SJ
Clin Lung Cancer; 2021 Nov; 22(6):549-561. PubMed ID: 34294595
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
Aredo JV; Mambetsariev I; Hellyer JA; Amini A; Neal JW; Padda SK; McCoach CE; Riess JW; Cabebe EC; Naidoo J; Abuali T; Salgia R; Loo BW; Diehn M; Han SS; Wakelee HA
J Thorac Oncol; 2021 Jun; 16(6):1030-1041. PubMed ID: 33588109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
